Results for tag: "MAGE-A3"

MAGE-A3 is a cancer vaccine developed to target the MAGE-A3 antigen, which is expressed in a variety of tumors. It is designed to stimulate the body's immune system to recognize and attack cancer cells. The MAGE-A3 market is a subset of the larger cancer vaccine market, which is estimated to be worth billions of dollars. MAGE-A3 is a therapeutic cancer vaccine, meaning it is used to treat existing cancer rather than prevent it. It is used to treat melanoma, non-small cell lung cancer, and bladder cancer. It is administered as an injection and is typically used in combination with other treatments such as chemotherapy or radiation. The MAGE-A3 market is highly competitive, with several companies developing and marketing their own versions of the vaccine. These companies include GlaxoSmithKline, Merck, Bristol-Myers Squibb, and AstraZeneca. Show Less Read more